DE69713402D1 - Liganden des neuropeptids y - Google Patents
Liganden des neuropeptids yInfo
- Publication number
- DE69713402D1 DE69713402D1 DE69713402T DE69713402T DE69713402D1 DE 69713402 D1 DE69713402 D1 DE 69713402D1 DE 69713402 T DE69713402 T DE 69713402T DE 69713402 T DE69713402 T DE 69713402T DE 69713402 D1 DE69713402 D1 DE 69713402D1
- Authority
- DE
- Germany
- Prior art keywords
- ligands
- neuropeptid
- neuropeptide
- formula
- agonists
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003446 ligand Substances 0.000 title abstract 2
- 101710151321 Melanostatin Proteins 0.000 abstract 2
- 102400000064 Neuropeptide Y Human genes 0.000 abstract 2
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 abstract 2
- 239000000556 agonist Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/24—Y being a hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2579196P | 1996-08-23 | 1996-08-23 | |
| PCT/US1997/014854 WO1998007420A1 (en) | 1996-08-23 | 1997-08-22 | Neuropeptide-y ligands |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69713402D1 true DE69713402D1 (de) | 2002-07-18 |
| DE69713402T2 DE69713402T2 (de) | 2002-11-07 |
Family
ID=21828075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69713402T Expired - Fee Related DE69713402T2 (de) | 1996-08-23 | 1997-08-22 | Liganden des neuropeptids y |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6849733B1 (de) |
| EP (1) | EP0984778B1 (de) |
| JP (1) | JP2001502296A (de) |
| AT (1) | ATE218859T1 (de) |
| AU (1) | AU4159297A (de) |
| CA (1) | CA2268051A1 (de) |
| DE (1) | DE69713402T2 (de) |
| DK (1) | DK0984778T3 (de) |
| ES (1) | ES2176776T3 (de) |
| PT (1) | PT984778E (de) |
| WO (1) | WO1998007420A1 (de) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9703414D0 (sv) * | 1997-09-23 | 1997-09-23 | Astra Ab | New compounds |
| SE9802207D0 (sv) * | 1998-06-22 | 1998-06-22 | Astra Pharma Inc | Novel compounds |
| SE9802206D0 (sv) * | 1998-06-22 | 1998-06-22 | Astra Pharma Inc | Novel compounds |
| EP1033366A3 (de) * | 1999-02-18 | 2000-12-27 | Pfizer Products Inc. | Amid-Derivate mit Neuropeptid Y (NPY) -antagonistischer Wirkung |
| US6355807B1 (en) | 1999-08-24 | 2002-03-12 | Agouron Pharmaceuticals, Inc. | Efficient synthetic routes for the preparation of rhinovirus protease inhibitors and key intermediates |
| US6774243B2 (en) | 1999-08-24 | 2004-08-10 | Agouron Pharmaceuticals, Inc. | Efficient synthetic routes for the preparation of rhinovirus protease inhibitors and key intermediates |
| DZ3415A1 (fr) | 2000-08-31 | 2002-03-07 | Chiron Corp | Guanidinobenzamides comme mc4-r agonistes. |
| CA2425285A1 (en) * | 2000-10-30 | 2002-05-10 | Warner-Lambert Company Llc | Amidino-urea serotonin receptor ligands and compositions, their pharmaceutical uses, and methods for their snythesis |
| ATE348097T1 (de) | 2001-04-09 | 2007-01-15 | Chiron Corp | Guanidinoverbindungen als melanocortin-4-rezeptor (mc4-r) agonisten |
| WO2003099818A1 (en) | 2002-05-23 | 2003-12-04 | Chiron Corporation | Substituted quinazolinone compounds |
| JP4806628B2 (ja) | 2003-05-05 | 2011-11-02 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤 |
| JP2007501861A (ja) | 2003-05-23 | 2007-02-01 | カイロン コーポレイション | Ｍｃ４−ｒアゴニストとしてのグアニジノ置換キナゾリノン化合物 |
| EP2338490A3 (de) | 2003-11-03 | 2012-06-06 | Probiodrug AG | Zusammenstellungen zur Behandlung von neuronalen Erkrankungen |
| WO2005051391A1 (en) | 2003-11-19 | 2005-06-09 | Chiron Corporation | Quinazolinone compounds with reduced bioaccumulation |
| US7304086B2 (en) | 2004-02-05 | 2007-12-04 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| WO2006108218A1 (en) * | 2005-04-15 | 2006-10-19 | Regenertech Pty Limited | Use of neuropeptide y (npy) and agonists and antagonists thereof for tissue regeneration |
| US7273882B2 (en) * | 2005-06-21 | 2007-09-25 | Bristol-Myers Squibb Company | Aminoacetamide acyl guanidines as β-secretase inhibitors |
| CN102775396B (zh) | 2005-11-08 | 2014-10-08 | 沃泰克斯药物股份有限公司 | Atp-结合弹夹转运蛋白的杂环调控剂 |
| US7671221B2 (en) | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| US7657504B2 (en) * | 2006-10-10 | 2010-02-02 | Microsoft Corporation | User interface for displaying images of sights |
| US7754739B2 (en) | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
| EP2089383B1 (de) | 2006-11-09 | 2015-09-16 | Probiodrug AG | 3-hydroxy-1,5-dihydropyrrol-2-one derivate als inhibitoren von glutaminylcyclase zur behandlung von geschwüren, krebs und anderen krankheiten |
| US9126987B2 (en) | 2006-11-30 | 2015-09-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| AU2008220785B2 (en) | 2007-03-01 | 2013-02-21 | Vivoryon Therapeutics N.V. | New use of glutaminyl cyclase inhibitors |
| JP5667440B2 (ja) | 2007-04-18 | 2015-02-12 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体 |
| CN104447716A (zh) | 2007-05-09 | 2015-03-25 | 沃泰克斯药物股份有限公司 | Cftr调节剂 |
| MX365732B (es) | 2007-12-07 | 2019-06-12 | Vertex Pharma | Procesos para producir acidos cicloalquilcarboxamido-piridin benzoicos. |
| EP3683218B1 (de) | 2007-12-07 | 2024-09-18 | Vertex Pharmaceuticals Incorporated | Feste formen von 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-yl)-cyclopropancarboxamido)-3-methylpyridin-2-yl)benzoesäure |
| NZ720282A (en) | 2008-02-28 | 2017-12-22 | Vertex Pharma | Heteroaryl derivatives as cftr modulators |
| JP5934645B2 (ja) | 2009-09-11 | 2016-06-15 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体 |
| WO2011107530A2 (en) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Novel inhibitors |
| JP5688745B2 (ja) | 2010-03-10 | 2015-03-25 | プロビオドルグ エージー | グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤 |
| JP2013523833A (ja) | 2010-04-07 | 2013-06-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の医薬組成物およびその投与 |
| WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
| EP2686313B1 (de) | 2011-03-16 | 2016-02-03 | Probiodrug AG | Benzimidazolderivate als glutaminylcyclase-hemmer |
| NZ727015A (en) | 2012-01-25 | 2017-12-22 | Vertex Pharma | Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| AU2014349010C1 (en) | 2013-11-12 | 2020-08-06 | Vertex Pharmaceuticals Incorporated | Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases |
| RU2691136C2 (ru) | 2014-11-18 | 2019-06-11 | Вертекс Фармасьютикалз Инкорпорейтед | Способ проведения высокопроизводительной тестовой высокоэффективной жидкостной хроматографии |
| JP6792636B2 (ja) * | 2016-11-25 | 2020-11-25 | 日本曹達株式会社 | グアニジン化合物および殺菌剤 |
| ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4562209A (en) * | 1981-08-24 | 1985-12-31 | William H. Rorer, Inc. | Promotion of feed efficiency in animals |
| WO1983000625A1 (en) * | 1981-08-24 | 1983-03-03 | Studt, William, Lyon | Treatment of coccidial infections with amidinourea or amidinothiourea derivatives |
| US5380945A (en) * | 1989-06-21 | 1995-01-10 | Abbott Laboratories | Guanidino compounds as regulators of nitric oxide synthase |
| ES2058651T3 (es) * | 1990-03-30 | 1994-11-01 | Heumann Pharma Gmbh & Co | Uso derivados de guanidina para la fabricacion de un medicamento con actividad antagonista de npy. |
| US5482947A (en) * | 1990-11-19 | 1996-01-09 | Talley; John J. | Retroviral protease inhibitors |
| US5583238A (en) * | 1990-11-19 | 1996-12-10 | G. D. Searle & Co. | Method for making intermediates useful in synthesis of retroviral protease inhibitors |
| DE4301452A1 (de) * | 1993-01-20 | 1994-07-21 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| DE4326465A1 (de) * | 1993-01-20 | 1995-02-09 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| FR2701480B1 (fr) | 1993-02-15 | 1995-05-24 | Sanofi Elf | Composés à groupe sulfamoyle et amidino, leur procédé de préparation et les compositions pharmaceutiques les contenant. |
| IL115613A0 (en) | 1994-10-20 | 1996-01-19 | Lilly Co Eli | Bicyclic neuropeptide y receptor antagonists |
| US6562862B1 (en) | 1994-10-20 | 2003-05-13 | Eli Lilly And Company | Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y |
| WO1996014307A1 (en) | 1994-11-07 | 1996-05-17 | Pfizer Inc. | Certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands |
-
1997
- 1997-08-22 JP JP10511019A patent/JP2001502296A/ja not_active Ceased
- 1997-08-22 PT PT97939524T patent/PT984778E/pt unknown
- 1997-08-22 ES ES97939524T patent/ES2176776T3/es not_active Expired - Lifetime
- 1997-08-22 US US08/916,527 patent/US6849733B1/en not_active Expired - Fee Related
- 1997-08-22 AT AT97939524T patent/ATE218859T1/de not_active IP Right Cessation
- 1997-08-22 DK DK97939524T patent/DK0984778T3/da active
- 1997-08-22 EP EP97939524A patent/EP0984778B1/de not_active Expired - Lifetime
- 1997-08-22 CA CA002268051A patent/CA2268051A1/en not_active Abandoned
- 1997-08-22 AU AU41592/97A patent/AU4159297A/en not_active Abandoned
- 1997-08-22 WO PCT/US1997/014854 patent/WO1998007420A1/en not_active Ceased
- 1997-08-22 DE DE69713402T patent/DE69713402T2/de not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ES2176776T3 (es) | 2002-12-01 |
| US6849733B1 (en) | 2005-02-01 |
| ATE218859T1 (de) | 2002-06-15 |
| DE69713402T2 (de) | 2002-11-07 |
| CA2268051A1 (en) | 1998-02-26 |
| EP0984778A1 (de) | 2000-03-15 |
| EP0984778A4 (de) | 2000-06-07 |
| EP0984778B1 (de) | 2002-06-12 |
| AU4159297A (en) | 1998-03-06 |
| WO1998007420A1 (en) | 1998-02-26 |
| DK0984778T3 (da) | 2002-09-16 |
| PT984778E (pt) | 2002-09-30 |
| JP2001502296A (ja) | 2001-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE218859T1 (de) | Liganden des neuropeptids y | |
| UY34152A (es) | ?oxazolidinonas substituidas y su uso?. | |
| SK86699A3 (en) | Nitrogen containing heteroaromatics as factor xa inhibitors | |
| EP0599532A3 (de) | Härtbare Einkomponenten-Organosiloxanzusammensetzungen. | |
| DK0572166T3 (da) | Hidtil ukendte 7beta-substitueret-4-aza-5beta-androstan-3-oner som 5beta-reduktaseinhibitorer | |
| AU1980997A (en) | Synthetic Multimerizing Agents | |
| BG104670A (en) | 4-(2-keto-1-benzimidazolinyl)piperidinne compounds as orl1-receptor agonists | |
| BR9808491A (pt) | Compostos calcilìticos | |
| ATE228111T1 (de) | M-amidinophenyl-analoga als faktor-xa-inhibitoren | |
| BG103310A (en) | Benzonaphthyridins as bronchial therapeutical means | |
| IT1269176B (it) | Eterobicicli ad attivita' fungicida | |
| SE0004245D0 (sv) | Novel compounds and their use | |
| SG52766A1 (en) | Organic compounds | |
| TR199903014T2 (xx) | 5-HT1F Agonistleri olarak yararl� karboksamitler. | |
| ATE245642T1 (de) | Benzamide mit tetrahydrofuranyloxy-substituenten als inhibitoren der phosphodiesterase 4 | |
| NO981393D0 (no) | Guanidinoproteasehemmere | |
| BG105539A (bg) | Елетриптан хидробромид монохидрат | |
| GB2324091A (en) | Metalloproteinase inhibitors | |
| DK1204659T3 (da) | Serotonerge benzofuraner | |
| RU95106653A (ru) | Производные 2-имидазолин-5-онов и 2-имидазолин-5-тионов и фунгицидные композиции на их основе | |
| DK1377574T3 (da) | 6-phenylbenzonaphtyridiner | |
| EA199900534A1 (ru) | Имидазопиридазины | |
| ATE280169T1 (de) | Serotonerge benzothiophene | |
| FR2693911B1 (fr) | Nouvelles utilisations d'un appareillage d'électro-anesthésie. | |
| TR200100133T2 (tr) | FKBP İnhibitörleri |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |